1. Home /
  2. Life Sciences

Life Sciences

Here's How Johnson & Johnson Stock Looks Ahead of Earnings

All eyes will be on JNJ as it releases its numbers Tuesday.

Medtronic Needs to Rebase Before Being Attractive Again

Stand aside and let things "shake out".

Is Soaring Repligen a Buy on This Pullback?

A double in five months has my attention.

Prospective Pickings Are Slim for This Annual Portfolio of Unloved Losers

The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.

3 Smaller Healthcare Stocks That Still Look Like Values in a Pricey Market

ProQR Therapeutics, Oscar Health and Hims & Hers Health appear to have promising futures.

Does Cardiff Oncology Pass the Speculative Test?

After watching the moves in Trillium Therapeutics, a Real Money reader wants to play CRDF. Here's the what the charts say.

Cramer Says 'Buy' for Intuitive Surgical, but What Do the Charts Say?

Let's see if his intuition is right on ISRG.

Cramer OK's OncoCyte as a Speculative Play. What Do the Charts Say?

Here's how to approach the diagnostics company for both the aggressive and timid.

Our Technical Strategy for Speculative Anavex Life Sciences

Let's check the charts and indicators.

BNGO! Looks Like Bionano Genomics Could Be a Winner

Here's why the current weakness in Bionano Genomics could be a buying opportunity.